← Back to Search

HPV Vaccine Optimization Strategies for Human Papillomavirus

N/A
Recruiting
Led By Noel T Brewer, PhD
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from 13 months to 24 months
Awards & highlights
No Placebo-Only Group

Summary

This trial studies how to increase HPV vaccine use in primary care clinics, with communication training and tools to optimize standing orders. #covid19

Who is the study for?
This trial is for primary care clinics that vaccinate children aged 9-12 against HPV but have vaccination rates below 72%. Clinics must have standing orders for the vaccine, which they either don't use routinely or are willing to adopt. Staff must complete a follow-up survey. Children and clinics not meeting these criteria are excluded.
What is being tested?
The study tests whether communication training combined with optimized standing orders increases HPV vaccination rates in clinics. Some clinics will receive only training, while others will get both training and tools to improve their standing order usage.
What are the potential side effects?
Since this trial focuses on staff training and procedural changes rather than medical interventions, there aren't direct side effects like those associated with drugs or vaccines.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from 13 months to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from 13 months to 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Estimated recommendation frequency, 11-12 year olds
Estimated recommendation frequency, 9-10 year olds
Estimated time spent on recommendations
+15 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: HPV vaccine communication training and standing orders optimizationExperimental Treatment1 Intervention
Staff in clinics randomized to this arm will receive the AAT and conduct a set of activities to optimize use of HPV vaccine standing orders.
Group II: HPV vaccine communication trainingExperimental Treatment1 Intervention
Staff in clinics randomized to this arm will receive an intervention called Announcement Approach Training (AAT). This training is designed to improve communication about HPV vaccination.

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor
365 Previous Clinical Trials
92,686 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,957 Previous Clinical Trials
41,112,083 Total Patients Enrolled
Noel T Brewer, PhDPrincipal InvestigatorUniversity of North Carolina
8 Previous Clinical Trials
5,574 Total Patients Enrolled

Media Library

HPV vaccine communication training Clinical Trial Eligibility Overview. Trial Name: NCT05742386 — N/A
Human Papillomavirus Research Study Groups: HPV vaccine communication training, HPV vaccine communication training and standing orders optimization
Human Papillomavirus Clinical Trial 2023: HPV vaccine communication training Highlights & Side Effects. Trial Name: NCT05742386 — N/A
HPV vaccine communication training 2023 Treatment Timeline for Medical Study. Trial Name: NCT05742386 — N/A
~7 spots leftby Jun 2025